T he incidence of cardiovascular disease is higher in men than in premenopausal women but increases in postmenopausal women. Until recently, an abundance of epidemiological data suggested a role for estrogens in this atheroprotective effect. 1, 2 However, the protective effects of estrogen on cardiovascular diseases has become controversial these last years. The Heart and Estrogen/progestin Replacement Study (HERS) recently demonstrated the failure of hormonal replacement therapy (HRT) to increase survival in secondary prevention. 3 Because long-term trials evaluating the effect of HRT in primary prevention will conclude in several years, it is important to get insight into the vascular effects and mechanisms in the meantime.
The mechanism whereby this protection is attributable to favorable changes in blood lipids and lipoproteins accounts for approximatively one third of its effect, 1 but a number of studies in humans 4 as well as animals [5] [6] [7] strongly suggest a direct action on the arterial wall.
Endothelium is now recognized to play a crucial role in the physiology of circulation. In particular, endothelium generates nitric oxide (NO). This free radical messenger inhibits platelet aggregation, interferes with mononuclear cell adhesion, and relaxes the underlying smooth muscle cells. 8 -10 NO is generated by a family of 3 isoenzymes: neuronal NOsynthase (type I), inducible NO-synthase (type II), and endothelial NO-synthase (type III). NO synthase (NOS) III activity can be stimulated by agonists (such as acetylcholine) and by a mechanical stimulus (shear stress). The importance of NO in vascular biology has prompted intensive research into the effects of estrogens in the vascular EDRF activity in several species. In rabbit, rat, and guinea pig, endotheliumderived relaxing factor (EDRF) was reported to be enhanced in ovariectomized 17␤-estradiol (E 2 )-treated females compared with ovariectomized controls. [11] [12] [13] [14] [15] [16] In these models, the increase in EDRF activity in response to E 2 can be due to (1) an increase in NOS III expression, 17, 18 (2) an increase in NOS III activity, 15, 19 and (3) an increase in NO bioavailability, 20 because the production of superoxide anion, one of the major mechanisms responsible for NO degradation, was found to be decreased in response to E 2 . Altogether, these studies suggest that the estrogen induced augmentation of NO production by vascular endothelium may contribute to its vasculoprotective effects.
It was reported that basal release of endothelium-derived NO was significantly higher in aortas of intact male mice compared with intact female mice. 21 Surprisingly, and to the best of our knowledge, the effect of E 2 on EDRF activity has never been reported in female mice. Ovariectomized female C57Bl/6 mice were then given either placebo or E 2 and the thoracic aorta studied for EDRF activity, both under basal and stimulated conditions. Protein abundance of NOS III, II, and I was also investigated. The effect of E 2 has long been thought to be mediated by activation of estrogen receptor (ER)-␣. ER␣ is a ligand-dependent transcriptional activator that modulates gene expression in target cells not only in reproductive tissues, but also in bone and vessels. Moreover, ER␤ recently discovered and cloned from rat prostate, was found to be expressed in many other tissues, including injured arteries. 22 It has been suggested that ER␣ plays a role because the basal release of endothelium-derived NO is decreased in male ER␣-knockout mice compared with wild-type mice. 21 However, its role in the mediation of the E 2 effect in females has not been reported. To define whether ER␣ or ER␤ mediates the effect of E 2 , relaxation experiments were performed in ovariectomized transgenic mice in which either the ER␣ or ER␤ has been disrupted.
Finally, several studies recently investigated the short-term effect of E 2 on NO production in cultured endothelial cells. [23] [24] [25] [26] [27] [28] [29] As the respective importance of the short-versus long-term effects of E 2 has been reported only in cultured cells, we studied the effect of short-term E 2 exposure in isolated aortic segments. 
Materials and Methods

Materials
Animal Preparation
All experimental protocols were performed in accordance with the recommendations of the European Accreditation of Laboratory Animal Care. The animals were housed in stainless steel cages in groups of 5, kept in temperature-controlled facilities on a 12-hour light-dark cycle and fed normal laboratory mouse chow. Only female mice were used this study. Wild-type mice were C57Bl/6 (weight 18 to 22 g; Iffa-Credo, Les Oncins, France). Targeted disruption (knockout) of mouse ER␣ and ER␤ genes was performed by homologous recombination, resulting in ER␣-and ER␤-homozygous deficient mice (ER␣ Ϫ/Ϫ and ER␤ Ϫ/Ϫ ). 30 Six backcrosses with C57Bl/6 mice were performed. At 4-weeks old, the mice were anesthetized by injection of ketamine (150 mg/kg, IP) for bilateral ovariectomy. Two weeks later, the castrated animals received subcutaneously either placebo or a 0.1 mg 17␤-estradiol (E 2 ) pellet (Innovative Research of America) designed to release E 2 at 80 g/kg/day for 60 days. Fifteen days later, after 2 hours fasting, the mice were euthanized with an overdose of ketamine. The uterus was removed and weighed. The thoracic aorta was removed and cleaned of excess adventitial tissue. Serum hormone concentrations were measured as previously described. 31 
Isolated Vascular Ring Experiments
Four ring segments of 3 mm were obtained from the descending thoracic aorta (Figure 1 2 and maintained at 37°C. Tension was recorded with a linear force transducer. The resting tension was gradually increased to 1 g over a period of 45 minutes, and the ring segments exposed to 80 mmol/L KCl until the optimal tension for generating force during isometric contraction was reached. The vessels were left at this resting tension throughout the remainder of the study. They were contracted with Phe (3 mol/L) to determine maximal contraction and then precontracted to 80% of that value (Phe, 0.25 mol/L). When a stable contraction plateau had been reached, the rings were exposed cumulatively to either ACh (1 nmol/L to 30 mol/L),
. Experiments were performed in the presence of diclofenac (2 mol/L), except when indicated. For experiments without endothelium, the thoracic aorta was cannulated and dry air was insufflated for 5 minutes to desiccate, and thus destroy, the endothelium.
Basal NO production by aortic ring was evaluated from the contraction elicited after 30 minutes with L-NA (final concentration: 100 mol/L) added to rings preconstricted for 30 minutes with the thromboxane A 2 mimetic U46619 (7.5 nmol/L). 21 Data were collected by Acknowledge software (Biopac System, Inc) and relaxation expressed as the percentage tension decrease below the tension elicited by precontracting the aortic rings with Phe.
Western Blotting Analysis
Thoracic aorta were frozen in liquid nitrogen, ground, and then suspended in boiling 2% SDS. Western blotting was performed has previously described, 20 
Statistical Analysis
Data were expressed as meanϮSEM. Comparisons of concentrationresponse relaxations between the various aortic segments studied were made by 1-factor ANOVA. Comparisons of data between different groups were made with repeated measures and a Sheffe's post hoc test used when differences were indicated. To test the respective roles of E 2 treatment and genotype on NO production, a 2-way ANOVA was performed. When an interaction was observed between the 2 factors, the effect of E 2 treatment was studied in each genotype using a t test. A value of PϽ0.05 was considered as statistically significant.
Results
Basal NO Production and Relaxation of Upper and Lower Segments of the Thoracic Aorta From Ovariectomized Wild-Type Mice
The basal NO release, estimated from the additional L-NAinduced contraction obtained in U-46619 precontracted rings, was similar in the 4 segments ( Figure 2 and online Table 2 in Figure 1 . The thoracic aorta, from the aortic arch to the lower part (just above the diaphagm) with the 4 segments of the thoracic aorta used in the present study: a, b, c, and d.
the online data supplement available at http://www.circresaha. org). The contraction in response to ␣1-adrenergic agonist phenylephrine was similar in the 4 segments studied (online Table 1 ). When the vessels were precontracted to 80% of the maximal contraction by phenylephrine, the maximal relaxation in response to acetylcholine was significantly decreased in the upper segment (a) as compared with the 2 lower segments (c and d), segment b being intermediate. The EC 50 of the upper segment (a) was higher than that of the 2 lower segments (c and d). The responses of segments c and d were similar. In response to the calcium ionophore A23187, to ATP, and to sodium nitroprusside, EC 50 and maximal relaxation were similar in all 4 segments (online Table 1 ).
Effect of E 2 Treatment on Body and Uterus Weight
Ovariectomized mice implanted with a placebo pellet showed nondetectable (Ͻ5 pg/mL IE, Ͻ20 pmol/L) circulating levels of E 2 , whereas those implanted with a pellet-releasing E 2 80 g/kg/day showed plasma E 2 concentrations averaging 0.5 nmol/L, irrespective of the genotype (online Table 2 ). Ovariectomized placebo-treated mice showed atrophied uterus (Ͻ20 mg), whereas both wild-type and ER␤ Ϫ/Ϫ mice treated with E 2 showed a significant increase in uterine weight, indicating the expected effect of E 2 on this target sexual organ (online Table 2 ). In contrast, ER␣ Ϫ/Ϫ mice conserved an atrophied uterus even when treated with E 2 (online Table 2 ).
Effect of E 2 Treatment on Aortic Contraction and Relaxation in Wild-Type Mice
E 2 did not significantly alter the contraction in response to phenylephrine and to U46619 (online Table 1 ). Basal NO release was significantly enhanced by E 2 in the 4 segments (Pϭ0.03) (Figure 2 ). EDRF activity, estimated from the relaxation of precontracted vessels in response to acetylcholine, was decreased by E 2 treatment. The EC 50 was significantly increased (on average 3-fold) and the maximal relaxation was significantly decreased (on average 30%) by E 2 in comparison to the placebo group (Pϭ0.03) (Figure 3 and online Table 1 ). The sensitivity to carbachol, a nonhydrolyzable activator of muscarinic receptors, was also decreased by E 2 . In contrast, there was no significant difference in relaxation between the 2 groups in response to ATP or to the calcium ionophore A23187 (Figure 3 and online Table 1 ). The maximal relaxation in response to the NO-releasing agent sodium nitroprusside (SNP) was not influenced by E 2 , whereas the EC 50 was increased (2-to 3-fold) in the E 2 -treated group (Figure 3 and online Table 1 ). We also performed experiments in de-endothelialized aortic rings. As shown in Figure 3E , destruction of endothelium induced a leftward shift of the dose response of both placebo-and E 2 -treated groups. Comparison of E 2 versus placebo-treated de-endothelialized rings revealed a slight but significant decrease in sensitivity to SNP ( Figure 3E and online Table 1 ).
Lack of Involvement of COX Pathway or Endothelium-Derived Hyperpolarizing Factor (EDHF) in Mouse Aortic Relaxation
In the placebo group, incubation of aortic segments with L-NA (100 mol/L) completely blocked ACh-elicited relaxation, demonstrating that NO was responsible for the relax- 
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ation. As all the previous experiments were performed on thoracic aorta contraction in the presence of the cyclooxygenase inhibitor diclofenac (2 mol/L), experiments were repeated in its absence. Similar results were obtained for all the parameters reported above in online 
E 2 Does Not Alter NOS I, II, and III Protein Abundance in Thoracic Aorta
Western blotting quantification did not reveal any changes in NOS III immunoreactivity in control or E 2 groups (Figure 4 ). The NOS II protein was slightly detected in thoracic aorta homogenates from both control and E 2 groups without significant differences between the 2 groups ( Figure 4 ). Whereas the antibody against NOS I recognized mouse NOS I in cerebellum homogenates, we did not detect any signal in the thoracic aorta homogenates, suggesting that the abundance of the immunoreactive protein was below the threshold of detection.
Effect of E 2 Treatment on Aortic Contraction and Relaxation in Mice Deficient in Either ER␣ or in ER␤
Contraction was similar in all categories of mice implanted with a placebo pellet, irrespective of the genotype (online Table 2 ). Two-factor ANOVA revealed an interaction (Pϭ0.02) between E 2 treatment and the genotype for basal NO release. E 2 treatment significantly increased basal NO release in wild-type and ER␤ Ϫ/Ϫ mice, but had no effect in ER␣ Ϫ/Ϫ animals ( Figure 5A and online Table 2 ). Likewise, in lower segments cd, 2-factor ANOVA revealed an interaction between E 2 treatment and the genotype for the EC 50 and E max of ACh-elicited relaxation (Pϭ0.05 and Pϭ0.036, respectively). E 2 treatment significantly decreased the sensitivity to ACh in wild-type mice (EC 50 , Pϭ0.014; E max , PϽ0.001), but had no effect in ER␣ Ϫ/Ϫ (EC 50 , Pϭ0.56; E max , Pϭ0.51) ( Figure 5B and online Table 2 ). Although the alteration of ACh-elicited relaxation tended to be greater in E 2 -treated ER␤ Ϫ/Ϫ mice than in E 2 -treated wild-type mice, the difference was not statistically significant (EC 50 , Pϭ0.35). Analogous results were obtained with segments a and b.
Abundant ER␣ immunoreactivity was detected in the uterine homogenates from wild-type and ER␤ Ϫ/Ϫ at the expected size (65 kDa), whereas it was undetectable in ER␣ Ϫ/Ϫ mice ( Figure 5C ). ER␣ immunoreactivity was also detected in the thoracic aorta homogenates from the wildtype, and E 2 treatment had no effect on ER␣ abundance. ER␣ was undetectable in ER␣ Ϫ/Ϫ mice. ER␣ immunoreactivity was also detected in the aorta homogenates from ER␤ Ϫ/Ϫ mice (not shown).
Effect of Short-Term E 2 Exposure on Aortic Rings
To investigate the extent to which short-term E 2 exposure elicits an alteration of NO production similar to that observed in long-term impregnation, 2 kinds of experiments in aortic segments from castrated mice were undertaken. First, 10 nmol/L E 2 was added to U46619-precontracted aortic rings from both placebo-and E 2 -treated mice. No change in vessel tone was detected in the 30 minutes following the addition of E 2 in the organ bath (nϭ3, not shown). Second, the relaxation in response to ACh was studied before and after a 15-minute period of incubation with 10 nmol/L E 2 . Again, no change was detected after short-term E 2 exposure (nϭ3, not shown).
Discussion
We first studied the relaxation of the thoracic aorta at the 4 different levels in castrated mice given placebo. The AChinduced relaxation in the lower parts of the aorta was significantly higher than that in the upper segments. A similar observation had been previously made in rabbit aorta 32 as well as in rat aorta. 33 It has obvious methodological implications, in particular the necessity to analyze the 4 segments separately, although the 2 lower segments (c and d) can be pooled. The lack of alteration following cyclooxygenase or EDHF inhibition, combined with the total abolition of relaxation after incubation with the NO synthase inhibitor L-NA, confirmed that ACh-induced relaxation was mainly dependent on NO. 34 Similarly, the contraction elicited after NO blockade by L-NA was not influenced by COX or EDHF inhibition.
We then studied long-term exposure to physiological levels of E 2 (ie, 0.5 nmol/L on average) on basal aortic NO production and relaxation. The contraction in response to U46619 and phenylephrine were not altered by E 2 , allowing the comparison of basal NO production and relaxation. Basal NO production is increased in castrated mice given E 2 . A similar effect of E 2 was previously reported in rabbit 19 and in rat. 15 The contraction elicited by NO blockade was independent of both cyclooxygenase derivatives and EDHF. It was also independent of extracellular superoxide, as superoxide dismutase (SOD) did not alter endothelium-dependent relaxation or basal NO production (not shown). Thus, decreased NO breakdown through an antioxidant effect of E 2 , previously reported in cultured bovine endothelial cells, 20 cannot account for the enhanced basal NO release in mouse. Surprisingly, we found that E 2 decreased ACh-elicited relaxation in all segments. This is the first report of a decrease in NO release in response to ACh on E 2 treatment. In other species, E 2 induced either an enhancement of ACh-elicited relaxation 15 or had no effect. 19, 35 Because similar results were obtained in response to carbachol, a nonhydrolyzable activator of muscarinic receptor, an increase in ACh degradation by acetylcholine esterase did not account for the observed effect. The sensitivity of the relaxation in response to SNP was slightly but significantly decreased in the E 2 -treated group, suggesting some degree of hyposensitivity to NO as a consequence of long-term E 2 exposure. This was observed both in intact and de-endothelialized rings. The hyposensitivity of vessel from E 2 -treated mice could have been the consequence of enhanced basal NO production, and this probably represents the counterpart to the classical observation of a supersensitivity to NO donors after suppression of endogenous NO. 36 Moreover, ACh did not show any constrictive effect on smooth muscle cells in the presence of L-NA or when the endothelium was removed irrespective of whether they had been treated with E 2 , showing that the endothelium is the sole target of ACh. Although the decrease in sensitivity to NO of E 2 -treated rings could contribute to the impairment of the relaxation in response to ACh, only part of this alteration could be explained by this factor for at least 2 reasons: (1) both the receptor-dependent (ATP) and the receptor-independent (A23187) endothelium-mediated relaxation remained normal after E 2 treatment; and (2) the magnitude of the alteration of the ACh-induced relaxation is larger than that to SNP.
Overall, these data suggest that the alteration elicited by E 2 in the aorta could be restricted to the M 3 muscarinic receptor or to its signal transduction pathway. The modulation of M 3 receptor-dependent signaling has been shown in rat myometrium. 37 Thus, the muscarinic receptor pathway can be a target for E 2 . However, in the aorta, this alteration appears to be not only restricted to 1 receptor type (ie, the muscarinic receptor) but also to 1 species (ie, the mouse). This again questions the physiological relevance of ACh for evaluation of endothelial function. ACh remains a pharmacological tool, and it has never been shown that a physiological stimulation of the muscarinic receptor of the endothelial aorta occurs in vivo. Moreover, in the present study, its effect does not correlate to the response to other more relevant pathophysiological stimuli such as ATP, which is released during platelet aggregation for instance. Finally, the effect of E 2 on ACh-elicited NO release is strictly the opposite of that induced on basal NO release. In order to clarify the effect of E 2 on endothelial NO production, we assessed the abundance of the 3 NO synthases. Western blot and subsequent quantification did not reveal any change in NOS III immunoreactivity in response to E 2 treatment. In addition, NOS II was detected although at a low level, whereas NOS I was not detected. The absence of change in NO synthase expression in aorta homogenates fits with the lack of effect of E 2 on A23187-induced relaxation.
It is tempting to link the increase in basal NO production in E 2 -treated mice to that recently reported by several independent groups in cultured endothelial cells. [23] [24] [25] [26] [27] Caulin-Glasser and colleagues 28 initially reported that E 2 rapidly increased NO production and the same group subsequently reported that the association between HSP-90 and NOS III following E 2 exposure could play a role in NOS III activation. Other groups 29 reported that within 5 minutes, E 2 induces a translocation of NOS III from the membrane to intracellular sites close to the nucleus. However, on more prolonged exposure to E 2 , most of the NOS III returns to the membrane, and thus probably cannot account for the long-term effects observed in the present work. Finally, Shaul's group 24 also reported that the nongenomic activation of NOS III by E 2 involves MAP kinase-dependent mechanisms and demonstrated that ER␣, localized in caveolae, can directly activate NOS III. 27 HSP-90 binds to both NOS III and ER␣, and these interactions could to promote the short-term E 2 -induced NOS III activity demonstrated in vitro. 38, 39 In this series of experiments, a physiological concentration of E 2 stimulated NO production within 5 to 30 minutes, according to the cultured endothelial cells models used. However, in the present study, short-term incubation with physiological levels of E 2 did not induce any changes in mouse aorta NO production. Thus, native endothelial cells in mouse (present study) and rat aorta (unpublished data) do not appear to respond to short-term E 2 as do cultured endothelial cells.
Transgenic mice allowed us to determine which ER gene was involved in the effect of E 2 on arterial NO production. ER␣ has long been considered as the unique target of E 2 , as it has been characterized in reproductive tissues, bone, and vessels, particularly in the endothelial cells. 40 However, it was initially suggested that ER␤ could mediate some effects of E 2 in the vessel wall. 41 The present work demonstrates that ER␣, but not ER␤, mediates the effects of E 2 on endothelial NO production, ie, the enhancement of basal NO release by endothelium and the alteration of ACh sensitivity. In addition, we recently demonstrated that ER␣ mediates the acceleration of reendothelialization of heat-damaged vessels in response to E 2 . 31 These studies indicate the prominence of the ␣ isoform of ER in the effect of E 2 on endothelium.
Does this increase in basal NO release contribute to the vasculoprotective effect of E 2 ? Several years ago, we tested this hypothesis in apolipoprotein E-deficient mice by blocking the production of NO. We found that the inhibition of NO synthase by L-NAME did not alter the protective effect of E 2 on fatty streak deposit. 42 Although we did not assess the decrease of NO production in the hypercholesterolemic mice, the prevention of fatty streak formation by E 2 appears independent of NO. In addition, in an external vascular cuff model, endogenous E 2 prevented the neointimal proliferation independently of NOS III. 43 However, this does not exclude that, in more advanced stages of atherosclerosis, the increase of NO production and/or the prevention of endothelial dysfunction could contribute to protecting the vessel against platelet aggregation and vasospasm, 2 major mechanisms leading to clinical cardiovascular events. Taking into account the crucial role of the endothelium in the maintenance of vascular integrity, endothelial ER␣ should be considered as a primordial target in pharmacological studies concerning cardiovascular diseases.
MS #3454 (old #2976)
Online Table I . Effect of E 2 treatment on aortic contraction (in response to phenylephrine and U46619) with and without endothelium, relaxation in response to acetylcholine (ACh), adNOS IIIine-5'-triphosphate (ATP), A23187 and sodium nitroprusside (SNP) with and without endothelium in the different aortic segments from ovariectomized C57Bl/6 mice treated either with placebo or E 2 . Values are means ± SEM from n=5-10 segments from 5 to 10 mice.
Onlinre Table II . Effect of E 2 treatment on body and uterine weights, plasma estradiol, aortic contraction (in response to phenylephrine and U46619), relaxation in response to acetylcholine (ACh), and basal NO in the different aortic segments from ovariectomized wild type (WT), ERα-homozygous deficient (ERα-/-) and ERβ-homozygous deficient (ERβ-/-) mice treated either with placebo or E 2 . Values are means ± SEM from n=5-10 segments from 5-10 mice. 
